MP78-12 DOES NEOADJUVANT CHEMOTHERAPY WITH GEMCITABINE AND CISPLATIN IN BLADDER CANCER INCREASE THE COMPLICATIONS AT RADICAL CYSTECTOMY IN HIGH AGE PATIENTS?

Abstract

You have accessJournal of UrologyBladder Cancer: Invasive VI1 Apr 2018MP78-12 DOES NEOADJUVANT CHEMOTHERAPY WITH GEMCITABINE AND CISPLATIN IN BLADDER CANCER INCREASE THE COMPLICATIONS AT RADICAL CYSTECTOMY IN HIGH AGE PATIENTS? Keishiro Fukumoto, Eiji Kikuchi, Suguru Shirotake, Kyohei Hakozaki, Yasumasa Miyazaki, Takahiro Maeda, Gou Kaneko, Shunsuke Yoshimine, Nobuhiro Tanaka, Kunimitsu Kanai, Masafumi Oyama, Yosuke Nakajima, Tetsuo Momma, and Mototsugu Oya Keishiro FukumotoKeishiro Fukumoto More articles by this author , Eiji KikuchiEiji Kikuchi More articles by this author , Suguru ShirotakeSuguru Shirotake More articles by this author , Kyohei HakozakiKyohei Hakozaki More articles by this author , Yasumasa MiyazakiYasumasa Miyazaki More articles by this author , Takahiro MaedaTakahiro Maeda More articles by this author , Gou KanekoGou Kaneko More articles by this author , Shunsuke YoshimineShunsuke Yoshimine More articles by this author , Nobuhiro TanakaNobuhiro Tanaka More articles by this author , Kunimitsu KanaiKunimitsu Kanai More articles by this author , Masafumi OyamaMasafumi Oyama More articles by this author , Yosuke NakajimaYosuke Nakajima More articles by this author , Tetsuo MommaTetsuo Momma More articles by this author , and Mototsugu OyaMototsugu Oya More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2560AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Although the survival benefit of neoadjuvant chemotherapy (NAC) for bladder cancer is well known, the safety for high age patients has not been fully evaluated. The aim of this study was to evaluate the effect of age on the safety of NAC with gemcitabine and cisplatin. METHODS We collected 419 patients who had undergone radical cystectomy for clinical anyTN0M0 bladder cancer from 2005 to 2015 at 7 institutions. Overall 251 (59.9%), 132 (31.5%), and 36 (8.6%) patients had cT2 or lower, cT3, and cT4 disease, respectively. All NACs were performed with gemcitabine and cisplatin. The complication was recorded according to the Clavien-Dindo classification. RESULTS The number of patients of < 60 age, 60-69 age, 70-79 age and ≥ 80 age were 58 (13.8%), 130 (31.0%), 173 (41.3%), and 58 (13.8%). NAC was performed in 16 (27.6%), 41 (31.5%), 50 (28.9%) and 9 (15.5%) patients in < 60 age, 60-69 age, 70-79 age and ≥ 80 age. The number of patients with >cT2 was 112 (37.0%) in non-NAC group, which was significantly lower than their counterparts (48.3%, 0.035). There were no other significant differences in clinical features according to NAC. In < 60 age group, the number of patients with complications, ileus, infections and wound troubles were 13 (31.0%), 4 (9.5%), 8 (19.0%) and 5 (11.9%) in non-NAC group. Those were 4 (25.0%), 2 (12.5%), 3 (18.8%) and 0 (0.0%) in NAC group. These differences were not significant (p=0.460, 0.534, 0.647 and 0.186, respectively). In 60-69 age group, the number of patients with complications, ileus, infections and wound troubles were 40 (44.9%), 15 (16.9%), 18 (20.2%) and 7 (7.9%) in non-NAC group. Those were 17 (41.5%), 6 (14.6%), 10 (24.4%) and 4 (9.8%) in NAC group. These differences were not significant (p=0.710, 0.749, 0.591 and 0.477, respectively). In 70-79 age group, the number of patients with complications, ileus, infections and wound troubles were 53 (43.1%), 16 (13.0%), 30 (24.4%) and 9 (7.3%) in non-NAC group. Those were 15 (30.0%), 2 (4.0%), 11 (22.0%) and 3 (6.0%) in NAC group. These differences were not significant (p=0.110, 0.079, 0.738 and 0.525, respectively). In ≥ 80 age group, the number of patients with complications, ileus, infections and wound troubles were 29 (59.2%), 14 (28.6%), 17 (34.7%) and 4 (8.2%) in non-NAC group. Those were 5 (55.6%), 1 (11.1%), 4 (44.4%) and 3 (33.3%) in NAC group. These differences were not significant (p=0.559, 0.257, 0.419 and 0.067, respectively). CONCLUSIONS NAC in bladder cancer can be performed safety regardless of age. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1041-e1042 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Keishiro Fukumoto More articles by this author Eiji Kikuchi More articles by this author Suguru Shirotake More articles by this author Kyohei Hakozaki More articles by this author Yasumasa Miyazaki More articles by this author Takahiro Maeda More articles by this author Gou Kaneko More articles by this author Shunsuke Yoshimine More articles by this author Nobuhiro Tanaka More articles by this author Kunimitsu Kanai More articles by this author Masafumi Oyama More articles by this author Yosuke Nakajima More articles by this author Tetsuo Momma More articles by this author Mototsugu Oya More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...